S

Saint-Louis Hospital | Infectious and Tropical Diseases Service

Research site

(Unclaimed)

Location

1 Avenue Claude VELLEFAUX, Paris, Île-de-France, France

Site insights

Top conditions

Top treatments

KRT-232

Ritonavir

Capecitabine

CTX

methotrexate

177Lu-PSMA-617

Tenofovir

Pembrolizumab

Maraviroc

Neratinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 34 total trials

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting

Metastatic Colorectal Cancer

Metastatic Colon Cancer

Drug: Fruquintinib

Drug: Placebo

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of...

Active, not recruiting

Multiple Myeloma

Drug: Selinexor

Drug: Dexamethasone

Evaluate the PK Efficacy Safety and Tolerability of Pegcetacoplan in Patients With Thrombotic Microangiopathy

The purpose of the study is to assess PK, Pharmacodynamics (PD), Efficacy and safety of pegcetacoplan in patients with TA-TMA after HSCT.

Enrolling

Transplant-Associated Thrombotic Microangiopathy

Drug: Pegcetacoplan

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...

Active, not recruiting

Acute Myeloid Leukemia

Drug: Uproleselan

Drug: Placebo

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-23...

Active, not recruiting

Acute Myeloid Leukemia

Drug: TL-895

Drug: KRT-232